Cardiology Research最新文献

{"title":"Achieving Neuroprotection in the Setting of Early Extubation During Infant Cardiac Surgery: A Prospective, Randomized, and Blinded Study.","authors":"Aymen N Naguib, Marc Bozych, Kelly McNally, Mark Galantowicz, Joseph Tobias","doi":"10.14740/cr2029","DOIUrl":"https://doi.org/10.14740/cr2029","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to investigate the impact of early extubation on stress response and neurodevelopmental outcomes after pediatric cardiac surgery utilizing cardiopulmonary bypass (CPB).</p><p><strong>Methods: </strong>In this single-center prospective pilot study, we attempted to study the impact of using dexmedetomidine as an adjunct to facilitate early extubation after pediatric cardiac surgery requiring CPB during the first year of life. The study was conducted between May 2014 and January 2020. Perioperative data and stress hormone levels were collected at different points during the perioperative period. In addition, neurodevelopmental outcome measures including cognitive composite score, language (expressive and receptive) and motor (fine and gross) composites were evaluated at five time points including prior to surgery and up to 1 year after the procedure. Two-sample <i>t</i>-tests and Kruskal-Wallis tests were used to compare continuous parametric and non-parametric outcomes, respectively. Fisher's exact or Chi-squared tests were used to compare categorical outcomes.</p><p><strong>Results: </strong>A total of 30 subjects were included in the final cohort of patients. Of the 30 subjects, 14 patients were randomized to the dexmedetomidine group (dexmedetomidine plus fentanyl) (DEX group) and 16 patients were randomized to the no dexmedetomidine group (fentanyl only) (no DEX group). With few exceptions, both groups demonstrated appropriate blunting of the stress response. There was a significant increase in the ratio of the pro-inflammatory interleukin-10 (IL-10) to the anti-inflammatory interleukin-6 (IL-6) for the no DEX group at the end of the procedure when compared to the DEX group (10 ± 9 vs. 5 ± 4, P = 0.04). When looking at the Bayley cognitive composite score, the DEX group scored better than the no DEX group during the second visit (102 ± 11 vs. 88 ± 17, P = 0.023). By the fifth visit, the two groups scored similarly (94 ± 12 vs. 94 ± 12, P = 0.9 for the no DEX and DEX groups, respectively).</p><p><strong>Conclusion: </strong>When looking at the neurodevelopmental outcome, both groups had no significant changes in their Bayley scores from baseline with blunting of most stress markers. This study offers possible evidence of the safety of early extubation after pediatric cardiac surgery while maintaining the goal of neuroprotection.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"16 3","pages":"178-188"},"PeriodicalIF":1.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12074690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Cardiac Lymphoma Presenting With Sick Sinus Syndrome and Atrial Flutter.","authors":"Tomo Komaki, Noriyuki Mohri, Akihito Ideishi, Takafumi Fujita, Kohei Tashiro, Tadaaki Arimura, Kanta Fujimi, Yuta Nakashima, Yasushi Takamatsu, Shin-Ichiro Miura, Masahiro Ogawa","doi":"10.14740/cr2072","DOIUrl":"https://doi.org/10.14740/cr2072","url":null,"abstract":"<p><p>Primary cardiac lymphoma is a rare, often fatal malignancy that can cause disorders of conduction depending on tumor location. We report two cases with sick sinus syndrome and atrial flutter secondary to primary cardiac lymphoma originating from the right atrium. One case required pacemaker implantation in the chronic phase after complete remission of lymphoma, and the other case in the acute phase when cardiac mass occupied the right atrium. Depending on the disease activity of lymphoma including its size, growth rate, and degree of invasion, the clinical course of sinus node dysfunction varies between each patient. In patients with conduction disorders, we suggest that long-term cardiac monitoring is necessary not only at onset but also after complete remission of lymphoma.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"16 3","pages":"289-294"},"PeriodicalIF":1.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12074686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progression of Atherosclerosis and Hypothesis on the Relationship Between Microvascular Dysfunction, Cardiovascular Risk, and Cancer.","authors":"Ansgar Adams, Waldemar Bojara, Michel Romanens","doi":"10.14740/cr2049","DOIUrl":"https://doi.org/10.14740/cr2049","url":null,"abstract":"<p><strong>Background: </strong>The extent of atherosclerosis in healthy men and women was measured using ultrasound in the carotid artery and whether the progression could be predicted using the classic risk factors was investigated. A hypothesis was also formulated as to how microvascular dysfunction and atherosclerosis, on the one hand, and cardiovascular disease and cancer, on the other hand, might be related. To describe the relationship between atherosclerosis and cancer, the classic risk factors and plaque burden were compared.</p><p><strong>Methods: </strong>From 2009 to 2024, 10,597 subjects (44% women) aged 20 - 65 years without signs of cardiovascular disease were examined using ultrasound of the carotid artery. The sum of all plaque areas (total plaque area (TPA)) and the maximum plaque thickness were measured. Follow-up examinations were carried out on 4,520 subjects (42% women) aged 40 - 65 years. In 2,397 men without cancer or cardiovascular events during follow-up, the classic risk factors and plaque burden were compared between 55 men who had a solid tumor and 188 men who had a cardiovascular event, and whether patients with cancer and a cardiovascular event exhibited different risk profiles was examined.</p><p><strong>Results: </strong>In the age group of 35 - 65 years, 12% of men and 4.2% of women had advanced atherosclerosis (types III and IVb). In the age group of 40 - 65 years, 2,592 men and 1,928 women were followed up. Low to moderate atherosclerosis was present in 2,052 (79.2%) men and 1,761 (91.3%) women. Advanced atherosclerosis developed in 139 (6.8%) men and 39 (2.2%) women, which could not be predicted by the classical risk factors (P > 0.05). The mean follow-up time was 73 months (6.1 years) for men and 75 months (6.3 years) for women. Patients without cancer or cardiovascular disease have lower risk factors and lower plaque burden compared to men with cancer or cardiovascular events. Patients with cancer have very similar high-risk factors and high plaque burden compared to patients with cardiovascular disease.</p><p><strong>Conclusion: </strong>By measuring the plaque burden on the carotid artery, a good risk stratification can be achieved in every age group. A follow-up examination every 3 - 5 years is advisable, as a rapid progression of the disease cannot be predicted taking into account the classic risk factors. Early treatment of advanced atherosclerosis improves the prognosis for cardiovascular diseases and possibly also for certain types of cancer. Patients with cancer and cardiovascular events show a similar risk profile and plaque burden.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"16 3","pages":"202-211"},"PeriodicalIF":1.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12074679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and Short-Term Outcomes of Heart Failure With Preserved and Mildly Reduced Ejection Fraction in Colombia: Insights of the Colombian Heart Failure Registry (RECOLFACA).","authors":"Lisbeth N Morales-Rodriguez, Alex Rivera-Toquica, Clara Saldarriaga, Rolando Palacio, Luis M Avila-Barros, Silfredo Arrieta-Gonzalez, Alfonso Munoz-Velasquez, Eduardo J Echeverry-Navarrete, Julian R Lugo-Pena, Juan A Ceron, Luis E Silva-Diazgranados, Hugo E Osorio-Carmona, Luis E Echeverria, Juan E Gomez-Mesa","doi":"10.14740/cr2015","DOIUrl":"https://doi.org/10.14740/cr2015","url":null,"abstract":"<p><strong>Background: </strong>Heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) has differences in therapy and development when compared with HF with reduced EF (HFrEF). We aimed to describe the clinical characteristics and all-cause mortality of patients with HFpEF/HFmrEF compared to those with HFrEF from the Colombian Heart Failure Registry (RECOLFACA).</p><p><strong>Methods: </strong>RECOLFACA included Colombian adult patients with ambulatory HF recruited from 2017 to 2019. All-cause mortality was our main outcome. We used the Kaplan-Meier method, life table, and Cox proportional hazard models to evaluate the role of the comorbidities on mortality, with a significant P-value of < 0.05. All statistical tests were two-tailed.</p><p><strong>Results: </strong>We included 2,514 patients, and 1,139 (45.3%) had a diagnosis of HFpEF or HFmrEF. HFpEF/HFmrEF diagnosis was not significantly related to either higher or lower risk of mortality compared to an HFrEF diagnosis; however, the individual risk factors for this outcome varied between the two groups. Health-related quality of life (HRQL) was a common risk factor for both groups.</p><p><strong>Conclusion: </strong>Although the EF classification was not a significant risk factor for mortality, patients with HFpEF/HFmrEF exhibited a unique profile of risk factors for mortality, the HRQL, highlighting the relevance of an adequate classification of the HF patients.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"16 3","pages":"267-277"},"PeriodicalIF":1.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12074688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Systematic Use of Fractional Flow Reserve and Optical Coherence Tomography on Percutaneous Coronary Intervention Outcomes in Patients With Diabetes.","authors":"Charantharayil Gopalan Bahuleyan, Selvamani Sethuraman, Fazila-Tun-Nesa Malik, Sridhar Kasturi, Manoj Bhavarilal Chopda, Rony Mathew Kadavil, Rajneesh Kapoor, Sanjeeb Roy, Rajpal Abhaichand, Ajit Menon, Vijayakumar Subban","doi":"10.14740/cr2052","DOIUrl":"https://doi.org/10.14740/cr2052","url":null,"abstract":"<p><strong>Background: </strong>Intracoronary imaging and physiology guidance of percutaneous coronary intervention (PCI) have shown significant improvements in clinical outcomes. However, comparable data on the use of these modalities in PCI of patients with diabetes are only sparsely available from South Asia. This study investigated the feasibility and clinical outcomes of systematic use of fractional flow reserve (FFR) and optical coherence tomography (OCT) during PCI in patients with diabetes.</p><p><strong>Methods: </strong>The study enrolled 275 patients (≥ 18 years) from nine centers in India and one from Bangladesh between October 2021 and September 2022. Patients with stable ischemic heart disease, non-ST-elevation myocardial infarction (MI), and unstable angina were included in the study. Angiographically intermediate lesions (diameter stenosis of 40% to 80%) underwent FFR-guided PCI. Lesions with a diameter stenosis of > 80% underwent PCI without FFR evaluation. All PCI procedures were guided by OCT using the MLD-MAX algorithm.</p><p><strong>Results: </strong>At 12 months, the target lesion failure (TLF) rate, a composite of cardiac death, nonfatal MI, and clinically driven target lesion revascularization, was 3.3%. Among the intermediate lesions, PCI was deferred by 70% after the FFR evaluation. Pre- and post-procedural OCT has led to a strategy change in 49.5% and 33.6%, respectively.</p><p><strong>Conclusions: </strong>The study revealed a relatively lower rate of events with FFR and OCT guidance compared to historical data from angiography-guided PCI in patients with diabetes. The strategy of combined use of FFR and OCT in PCI may contribute to improved clinical outcomes in patients with diabetes.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"16 3","pages":"278-288"},"PeriodicalIF":1.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12074682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dissecting Autophagy Gene Expression in Endothelial Cells of Pulmonary Arterial Hypertension at Single-Cell Resolution.","authors":"Chang Zhi Zhang, Qian Yu, Wei Jia Liu, Jing Han","doi":"10.14740/cr2055","DOIUrl":"https://doi.org/10.14740/cr2055","url":null,"abstract":"<p><strong>Background: </strong>Endothelial cell (EC) dysfunction is one of the pathogeneses of pulmonary arterial hypertension (PAH); autophagy is an important conserved mechanism for maintaining cellular homeostasis. However, to date, transcriptional signatures of autophagy-related genes during PAH are not well characterized.</p><p><strong>Methods: </strong>We analyzed the single-cell RNA sequencing (scRNA-seq) data and revealed the relationship between autophagy and PAH in EC from the perspective of differential expression, transcriptional signature typing, comparative analysis, pseudo-temporal changes of autophagy genes, and high dimensional weighted gene co-expression network analysis (hdWGCNA) networks of autophagy genes. Moreover, we established an <i>in vitro</i> PAH model and verified the expression signatures of candidate autophagy-related genes by western blotting. Student's <i>t</i>-test was used to detect data differences.</p><p><strong>Results: </strong>Single-cell data showed that ECs had three different subgroups, namely Endo-Nor (normal state), Endo-Mid (transition state), and Endo-PAH (PAH disease group). Functional enrichment analysis of differentially expressed genes between Endo-PAH and Endo-Nor showed that autophagy and phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathways were abnormal. Pseudo-temporal trajectory analysis showed that eight autophagy-related genes were involved in regulating PAH progression. Furthermore, the hdWGCNA network revealed six autophagy-related PAH progression genes. By comprehensively comparing different analysis methods, we identified <i>Ddit4</i> as an autophagy-related PAH biomarker. Western blot observed that DDIT4 protein was significantly upregulated (P < 0.01) in the PAH model.</p><p><strong>Conclusion: </strong>This study dissected the expression signature of autophagy genes in PAH at single-cell resolution and identified DDIT4 as a potential biomarker.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"16 3","pages":"238-249"},"PeriodicalIF":1.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12074683/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heart Conditioning as a Healthy Strategy in Management of Cardiac Enlargement.","authors":"David Wing-Ching Lee, William Wing-Ho Lee, Andrew Ying-Siu Lee","doi":"10.14740/cr2047","DOIUrl":"https://doi.org/10.14740/cr2047","url":null,"abstract":"<p><strong>Background: </strong>Remote ischemic conditioning (RIC) is widely recognized for its cardioprotective effects in the context of ischemic heart disease. Lately, it has been shown that heart conditioning can be utilized as a healthy strategy in the reversion of disease and aging. In this regard, we examine the impact of RIC on patients with cardiac enlargement.</p><p><strong>Methods: </strong>Forty-four patients with cardiac enlargement were prospectively enrolled and randomly assigned into RIC group (n = 22) and control group (n = 22). RIC protocol is 3-min inflation/deflation of the blood pressure cuff applied in the upper arm to create transient arm ischemia. RIC treatment was performed once a day for 1 year. Left atrial and ventricular dimensions and left ventricular ejection fraction (LVEF) were all assessed in two groups.</p><p><strong>Results: </strong>RIC was well-tolerated. After 1 year treatment, left atrial and ventricular dimensions were significantly decreased in the RIC group. Moreover, LVEF showed a significant increase, from 46.24% to 56.45% (P < 0.0001).</p><p><strong>Conclusion: </strong>The research indicates that a year-long healthy regimen of RIC treatment may effectively reverse cardiac enlargement, thereby endorsing the broader implementation of RIC in the daily routines of these patients.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"16 3","pages":"197-201"},"PeriodicalIF":1.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12074687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipid-Lowering Therapy in Post-Acute Coronary Syndrome Patients: An Observational Study.","authors":"Meshari S Alwagdani, Naeem Alshoaibi, Hossameldeen M Elghetany, Abdulrahman H Algrigri, Razan A Bahurmuz, Abdulwahab A Alqahtani, Zeyad T Olfat, Hatun Halawani","doi":"10.14740/cr2063","DOIUrl":"https://doi.org/10.14740/cr2063","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular disease remains a major cause of morbidity and mortality globally. International guidelines recommend aggressive lipid-lowering therapy (LLT) in patients with atherosclerotic cardiovascular disease (ASCVD), targeting a low-density lipoprotein cholesterol (LDL-C) level of < 55 mg/dL and a ≥ 50% reduction from baseline. However, real-world studies continue to show suboptimal LDL-C target achievement. This study aimed to assess the proportion of post-acute coronary syndrome (ACS) patients achieving both LDL-C < 55 mg/dL and a ≥ 50% reduction from baseline at 6 months. A secondary objective was to evaluate target achievement after 1 year and analyze outcomes across different LLT regimens.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study at a single tertiary center, including patients aged ≥ 18 years who presented with ACS between January 2021 and January 2022, underwent percutaneous coronary intervention (PCI), and had documented LDL-C levels at baseline and at least one follow-up within 12 months. Patients with baseline LDL-C ≤ 55 mg/dL or on ongoing LLT were excluded.</p><p><strong>Results: </strong>A total of 122 patients were included (mean age 63.5 years; 59.8% had both diabetes and hypertension). At 6 months, only 13/82 patients (15.9%) achieved the primary LDL-C target. The highest achievement was seen in the rosuvastatin + ezetimibe group (30.0%), followed by rosuvastatin (17.9%), atorvastatin + ezetimibe (14.3%), and atorvastatin monotherapy (14.0%). A ≥ 50% LDL-C reduction without meeting the < 55 mg/dL threshold was observed in 24/82 patients (29.3%).</p><p><strong>Conclusions: </strong>LDL-C target achievement remains low among post-ACS patients despite high-intensity statin use. Combination therapy with rosuvastatin + ezetimibe showed more favorable outcomes, particularly in older adults. These findings underscore the need for structured follow-up, treatment intensification, and broader use of advanced therapies such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to close the real-world treatment gap.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"16 3","pages":"250-258"},"PeriodicalIF":1.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12074677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Sufficient Cardiac Rehabilitation With a Wearable Activity Tracker in a Patient With Acute Myocardial Infarction and Residual Stenosis.","authors":"Takuro Matsuda, Yasunori Suematsu, Hiroyuki Fukuda, Etsumi Nakamura, Chie Matsushita, Kanta Fujimi, Shin-Ichiro Miura","doi":"10.14740/cr2066","DOIUrl":"10.14740/cr2066","url":null,"abstract":"<p><p>Guidelines recommend exercise-based cardiac rehabilitation (CR) 2 - 3 times per week. However, this high number of visits per week to outpatient CR can be a burden that lowers patient compliance. Home-based exercise is a key for patients to perform a sufficient volume of exercise. But we sometimes need to be careful in patients who has coronary artery stenosis. Wearable activity trackers would be useful for maintaining an appropriate intensity and sufficient volume of home-based exercise. A 65-year-old male patient who did not have unremarkable past medical history had chest pain and visited our hospital. The primary diagnosis was acute myocardial infarction and the culprit lesion which was 99% stenosis in the posterior descending artery of the left circumflex artery was successfully treated. He was also diagnosed with obesity, hypertension, diabetes mellitus, and dyslipidemia and had residual 75% stenosis in the left anterior descending artery. He was started pharmacotherapy and planned elective percutaneous coronary intervention after 5 months. He was required an exercise-based CR after discharge. Outpatient CR was scheduled for once a week and he needed additional home-based exercise. We used a wearable activity tracker (iAide2-W, TOKAI Corp, Gifu, Japan) to check appropriate intensity of exercise and maintain a sufficient volume for home-based exercise. This device was able to monitor the metabolic equivalent by an acceleration sensor by telemetry. We could check the intensity of exercise at a specialized online site. Thanks to this device, he was able to reduce the body weight and increase the exercise tolerance without any chest pain. The percent predicted oxygen intake per body weight increased from 84% to 95% at the anaerobic threshold and from 68% to 83% at the peak. After 5 months, he treated the residual stenosis successfully. Wearable activity trackers can be used to evaluate biological information in daily life and are expected to be useful for CR.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"16 4","pages":"380-384"},"PeriodicalIF":1.4,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144844527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Clinical Outcomes in Patients With Transthyretin Cardiac Amyloidosis Versus Non-Ischemic Cardiomyopathy.","authors":"Barbara C Okeke, Timothy Chrusciel, Mina M Benjamin","doi":"10.14740/cr2050","DOIUrl":"10.14740/cr2050","url":null,"abstract":"<p><strong>Background: </strong>We sought to compare the long-term outcomes in patients with transthyretin cardiac amyloidosis (CA) compared to those with non-ischemic cardiomyopathy (NICM) from a large healthcare system database.</p><p><strong>Methods: </strong>Patients with CA or NICM were identified from SSM Healthcare System's data warehouse using ICD codes. Inclusion criteria included at least 6 months of follow-up. Outcomes studied were heart failure hospitalization (HFH), ventricular tachyarrhythmias (VTA), implantable cardiac defibrillator (ICD) and pacemaker (PM) placement. Multivariate logistic analysis and Kaplan-Meier survival curves were constructed.</p><p><strong>Results: </strong>We identified 231 patients with CA and 462 with NICM, matched for age, race, and gender. CA patients had higher incidence of peripheral vascular disease (48.5% vs. 35.5%) and coronary artery disease (10.4% vs. 6.1%). Mean follow-up was 48.1 ± 33.1 months. CA patients had a higher rate of HFH (57.6% vs. 46.1%) and a lower rate of ICD (1.7% vs. 5.9%). In the multivariate model, CA patients had significantly higher odds for HFH (odds ratio: 1.86; 95% confidence interval: 1.29 - 2.68). Kaplan-Meier survival curves showed a trend toward earlier HFH and later PM or ICD implantation in CA patients.</p><p><strong>Conclusions: </strong>In this retrospective study from a large healthcare system database, compared to NICM, transthyretin CA patients had significantly higher rates of HFH, similar odds of VTA, and a lower likelihood of receiving an intracardiac device.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"16 2","pages":"102-109"},"PeriodicalIF":1.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}